ACADIA Pharmaceuticals Inc.
NASDAQ:ACADBiotechnology
-$0.13 today
- Market cap
- $3.08B
- Beta
- 0.83
- P/E (TTM)
- 9.7
- EPS (TTM)
- $2.20
Volume 1.89M
Average 1.66M
ACAD Account Payables
Amounts the company owes suppliers for goods and services received.
ACADIA Pharmaceuticals Inc.NASDAQ: ACAD
Account Payables · Q3 FY2026 · quarter ended Sep 2026
Account payables falls 24.9% from a year ago
Account payables stood at $16.33M at the end of Q3 FY2026, down 24.9% from a year earlier and down 63.4% from the prior quarter. Over 3 fiscal years it compounded at -5.1% a year.
Context
- Account payables amounted to 0.9% of total assets at the end of Q3 FY2026, down 0.7 pp from a year earlier.
- Account payables increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether account payables keeps falling in the next quarterly balance sheet after a -24.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Account Payables history
USD · from the balance sheet
- Latest · FY2025
- 10.9M USD
- Year-over-year change
- -32.7%
- 4-year CAGR
- +12.2%
| Period | Period end | Account Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 10.9M | -32.7% |
| FY2024 | 2024-12-31 | 16.19M | -7.7% |
| FY2023 | 2023-12-31 | 17.54M | +37.6% |
| FY2022 | 2022-12-31 | 12.75M | +85.4% |
| FY2021 | 2021-12-31 | 6.88M | — |
Account Payables vs competitors
How ACAD compares with its peers on the latest reported figures
- ACAD's Sep 2026 account payables of $16.33M is the 2nd highest of the 11 companies compared; the peer median is $4.76M.
- Its year-over-year change of -24.9% is the 6th highest of 11, against a peer median of -19.6%.
- Account payables amounts to 0.9% of total assets for ACAD, versus a peer median of 1.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $78.97M | -13.8% | +19.3% | 10.4% | |
| Sep 2026 | $16.33M | -24.9% | -5.1% | 0.9% | |
| Sep 2026 | $15.02M | -51.3% | +18.8% | 1.1% | |
LBRXLB Pharmaceuticals Inc Common Stock | Mar 2026 | $7.12M | +1021.1% | +138.9% | 1.8% |
RAPPRapport Therapeutics, Inc. Common Stock | Mar 2026 | $6.56M | +206.7% | +42.4% | 1.3% |
NMRANeumora Therapeutics, Inc. Common Stock | Mar 2026 | $5.06M | +380.7% | -22.1% | 3.3% |
| Mar 2026 | $4.47M | -25.3% | -27.0% | 1.0% | |
| Mar 2026 | $3.37M | +143.4% | +5.4% | 1.2% | |
| Dec 2025 | $2.64M | -42.2% | +3.6% | 2.0% | |
CTNMContineum Therapeutics, Inc. Class A Common Stock | Mar 2026 | $1.5M | -59.0% | +33.2% | 0.6% |
| Mar 2026 | $0 | -100.0% | — | 0.0% | |
| Peer median (excluding ACAD) | $4.76M | -19.6% | +18.8% | 1.3% | |
Competitors are the stored peer set for ACAD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 147.44M | 114.85M | 188.66M | 319.59M | 177.7M |
| Short-term Investments | 373.27M | 301.98M | 250.21M | 436.4M | 641.99M |
| Net Receivables | 65.34M | 63.08M | 102.35M | 104.7M | 148.23M |
| Inventory | 7.88M | 6.64M | 35.82M | 21.95M | 34.67M |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | 617.82M | 507.94M | 616.13M | 938.32M | 1.06B |
| Property, Plant & Equipment (Net) | 66.32M | 61.59M | 56.47M | 50.79M | 54.87M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 65.49M | 119.78M | 108.89M |
| Long-term Investments | 3.6M | 12.97M | 5.77M | 8.77M | 7.85M |
| Tax Assets | 0 | 0 | 0 | 0 | 249.88M |
| Other Non-current Assets | 12.38M | 5.31M | 5.1M | 70.1M | 80.6M |
| Total Non-current Assets | 82.3M | 79.88M | 132.83M | 249.44M | 502.08M |
| Total Assets | 700.12M | 587.81M | 748.96M | 1.19B | 1.56B |
| Account Payables | 6.88M | 12.75M | 17.54M | 16.19M | 10.9M |
| Short-term Debt | 0 | 0 | 9.41M | 0 | 11.63M |
| Tax Payables | 0 | 377K | 1.56M | 12.02M | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 25.9M | 49.51M | 92.31M | 36.55M | 67.83M |
| Total Current Liabilities | 96.07M | 125.63M | 254.25M | 394.87M | 277.11M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 7.03M | 9.07M | 15.15M | 18.06M | 19.14M |
| Total Non-current Liabilities | 63.16M | 61.77M | 62.95M | 60.09M | 59.69M |
| Total Liabilities | 159.23M | 187.4M | 317.2M | 454.96M | 336.81M |
| Common Stock | 16K | 16K | 16K | 16K | 16K |
| Retained Earnings | (2.15B) | (2.37B) | (2.43B) | (2.2B) | (1.81B) |
| Accumulated OCI | (192K) | (975K) | 24K | 292K | 1.45M |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 540.89M | 400.41M | 431.76M | 732.79M | 1.23B |
| Total Debt | 64.43M | 62M | 57.21M | 52M | 52.19M |
| Net Debt | (83.01M) | (52.85M) | (131.45M) | (267.59M) | (125.51M) |
ACADIA Pharmaceuticals Inc.
NASDAQ:ACAD
Intrinsic Alpha fair value
Locked
Current Price
$17.83
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.